Allogene Therapeutics Inc (ALLO) — Net Asset Momentum
Allogene Therapeutics Inc (ALLO) recorded a net asset momentum of -17.6% as of December 2024, with net assets of $422.18 Million USD. Net Asset Momentum measures the year-over-year percentage change in net assets (total assets minus total liabilities), indicating how rapidly the company is building or eroding its equity base. See Allogene Therapeutics Inc defensive interval ratio to measure how many days the company can operate on defensive assets alone.
YoY Momentum
Current Net Assets
Years of Data
Country
Allogene Therapeutics Inc Net Asset Momentum (2017–2024)
This chart tracks Allogene Therapeutics Inc's year-over-year net asset growth across 8 annual reporting periods from 2017 to 2024. The most recent momentum reading is -17.6%, with net assets of $422.18 Million USD as of December 2024. Read total liabilities of Allogene Therapeutics Inc for a breakdown of total debt and financial obligations.
Annual Net Asset History for Allogene Therapeutics Inc (2017–2024)
The table below shows the complete annual net asset history for Allogene Therapeutics Inc from 2017 to 2024, covering 8 yearly periods. Each row includes total assets, total liabilities, net assets, and the year-over-year momentum figure for that period. For live market cap and broader valuation context, see Allogene Therapeutics Inc market capitalisation.
| Year | Net Assets (USD) | Total Assets | Total Liabilities | YoY Momentum |
|---|---|---|---|---|
| 2024 | $422.18 Million | $548.71 Million | $126.53 Million | ▼ -17.6% |
| 2023 | $512.23 Million | $642.84 Million | $130.60 Million | ▼ -23.2% |
| 2022 | $666.88 Million | $821.58 Million | $154.70 Million | ▼ -27.9% |
| 2021 | $925.20 Million | $1.05 Billion | $125.63 Million | ▼ -14.3% |
| 2020 | $1.08 Billion | $1.23 Billion | $148.21 Million | ▲ +71.6% |
| 2019 | $629.02 Million | $717.80 Million | $88.78 Million | ▼ -10.5% |
| 2018 | $703.16 Million | $773.86 Million | $70.69 Million | ▲ +35158300.0% |
| 2017 | $-2.00K | $0.00 | $2.00K | — |